Experimental Cholesterol Drug Does Not Cut Risk for Cardiovascular Events (FREE)

By the Editors Evacetrapib, an experimental cholesterol ester transfer protein inhibitor, raises HDL cholesterol and lowers …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news